ClarVista Medical is a developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing, ClarVista was spun out from Prospex Medical, a medical device incubator, to pursue the development of the HARMONI™ IOL. Between 2012 and 2014, the company developed the first generation HARMONI™ system, conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system, conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.
Company Growth (employees)